Wednesday, Immutep Limited (NASDAQ:IMMP) released preliminary topline results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial evaluating eftilagimod alpha (efti) in combination with Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma patients (1L HNSCC) with negative PD-L1 expression.
The investigational immuno-oncology combination demonstrates an overall response rate (ORR) of 26.9% and disease control rate (DCR) of 57.7% in 26 patients whose tumors do not express PD-L1, which compares favorably to historical controls.
Martin Forster, TACTI-003 Investigator, stated, “These preliminary topline results in the first-line setting for patients with head and neck squamous cell ...